Aug 6, 2026 07:53AM
Jul 29, 2026 07:03AM
Jul 13, 2026 07:03AM
May 27, 2026 06:55AM
May 14, 2026 04:41PM
May 5, 2026 08:42AM
May 5, 2026 08:34AM Ocugen completes $115 million convertible notes offering to extend runway
Mar 25, 2026 09:22AM
Mar 25, 2026 06:55AM
Mar 11, 2026 06:03AM
Mar 4, 2026 08:19AM
Mar 4, 2026 08:15AM
Sep 30, 2025 06:05AM
Sep 18, 2025 11:02AM Ocugen merger agreement with Carisma terminated over funding shortfall
Aug 13, 2025 06:27AM
Aug 1, 2025 08:33AM
Jul 21, 2025 07:30AM
Jun 24, 2025 06:51AM
Jun 23, 2025 07:30AM
Jun 16, 2025 07:03AM
Jun 5, 2025 10:32AM Ocugen (OCGN) stock rises on Korean licensing deal for gene therapy
Jun 5, 2025 07:03AM
May 27, 2025 07:04AM
May 13, 2025 06:59AM
May 9, 2025 08:22AM
Mar 18, 2025 08:06AM
Mar 5, 2025 07:14AM
Mar 3, 2025 09:01AM Ocugen (OCGN) Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for St
Feb 27, 2025 08:48AM
Feb 13, 2025 06:50AM
Feb 12, 2025 07:45AM
Feb 3, 2025 06:31AM
Jan 27, 2025 06:31AM
Jan 13, 2025 06:31AM
Dec 19, 2024 06:40AM Ocugen (OCGN) Reports Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial
Nov 20, 2024 07:33AM
Nov 19, 2024 07:03AM
Nov 8, 2024 06:53AM
Oct 22, 2024 07:02AM
Oct 15, 2024 08:18AM
Oct 9, 2024 06:33AM
Aug 28, 2024 06:32AM Ocugen (OCGN) Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Trial
Aug 26, 2024 07:03AM
Aug 8, 2024 07:11AM
Aug 5, 2024 06:31AM
Aug 1, 2024 06:23AM
Jul 31, 2024 04:15PM
Jun 26, 2024 04:38AM
Jun 21, 2024 07:01AM Ocugen (OCGN) Announces Data and Safety Monitoring Board Approved Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease

446,166 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All